Theravance, Inc. (NASDAQ: THRX) reported today its financial results for the fourth quarter and year ended December 31, 2005. The net loss for the fourth quarter of 2005 was $42.2 million compared to $29.2 million during the same period of 2004, an increase of $13.0 million. The increase was primarily due to higher research and development costs associated with telavancin Phase 3 clinical programs.
